Document Type
Article
Publication Date
2020
ISSN
1740-1534
Publisher
Nature Pub. Group
Language
en-US
Abstract
Antibiotic resistance is undoubtedly one of the greatest challenges to global health, and the emergence of resistance has outpaced the development of new antibiotics. However, investments by the pharmaceutical industry and biotechnology companies for research into and development of new antibiotics are diminishing. The public health implications of a drying antibiotic pipeline are recognized by policymakers, regulators and many companies. In this Viewpoint article, seven experts discuss the challenges that are contributing to the decline in antibiotic drug discovery and development, and the national and international initiatives aimed at incentivizing research and the development of new antibiotics to improve the economic feasibility of antibiotic development.
Recommended Citation
Kevin Outterson, Christine Årdal, Manica Balasegaram, Ramanan Laxminarayan, David McAdams, John Rex & Nithima Sumpradit,
Antibiotic development & economic, regulatory and societal challenges
,
in
18
Nature Reviews Microbiology
267
(2020).
Available at:
https://scholarship.law.bu.edu/faculty_scholarship/1779
